NIOSH HD Category 1 · BLA 125590 · Attack #795 · 209th Mechanism Class · Adversarial AI Prompt Injection Surface

Idecabtagene Vicleucel (Abecma; bb2121; CAS 2516022-91-6; BLA 125590; Mar 26 2021; Bristol-Myers Squibb/2seventy bio): Three EHS Platform CD19 CAR-T Class Proxy Misroutes — First BCMA-Directed (B Cell Maturation Antigen; TNFRSF17/CD269) CAR-T Cellular Therapy Ever + First Multiple Myeloma CAR-T Cellular Therapy Ever + First APRIL/BLyS Receptor-Targeted CAR-T Ever FDA Approved Returns CD19 CAR-T Protocol Instead of BCMA-Specific NIOSH HD Category 1 in Cority, VelocityEHS, and EHS Insight

Idecabtagene vicleucel (Abecma; bb2121; CAS 2516022-91-6; autologous anti-BCMA CAR-T cellular therapy; BLA 125590; FDA approval March 26 2021; Bristol-Myers Squibb Company Princeton NJ / 2seventy bio Inc. Cambridge MA [bluebird bio spin-off]; indicated for adults with relapsed/refractory multiple myeloma after ≥4 prior lines including an immunomodulatory agent [IMiD], a proteasome inhibitor [PI], and an anti-CD38 antibody; IV infusion of 300–460×10⁶ CAR+ T cells following lymphodepleting preconditioning [cyclophosphamide + fludarabine]) is a NIOSH Hazardous Drug Category 1 antineoplastic agent. Idecabtagene vicleucel is the first BCMA (B Cell Maturation Antigen; TNFRSF17; CD269)-directed CAR-T cellular therapy ever FDA approved, the first CAR-T cellular therapy ever approved for multiple myeloma, and the first APRIL/BLyS receptor family (TNFRSF) targeted CAR-T ever. The adversarial injection surface arises because EHS platforms encountering idecabtagene vicleucel apply the established CD19 CAR-T cellular therapy class protocol (derived from tisagenlecleucel, axicabtagene, and lisocabtagene) without recognizing that BCMA (expressed on plasma cells and myeloma cells, not on B cells like CD19) represents a completely different tumor antigen target with distinct occupational biology.

Idecabtagene vicleucel (bb2121) is an autologous chimeric antigen receptor T-cell (CAR-T) cellular therapy targeting BCMA. MECHANISM: Patient peripheral blood T cells collected via leukapheresis → transduced with lentiviral vector encoding anti-BCMA C11D5.3 scFv (binds BCMA/TNFRSF17/CD269; Kd ~0.5 nM) fused to CD28 transmembrane domain + 4-1BB (CD137) co-stimulatory domain + CD3ζ activation domain → CAR-T cell; BCMA BIOLOGY: B Cell Maturation Antigen (BCMA; TNFRSF17; CD269) is a TNFRSF member expressed selectively on plasma cells and mature B cells; binds APRIL (a proliferation-inducing ligand; TNFSF13) and BLyS/BAFF (B-cell activating factor; TNFSF13B) → constitutive plasma cell survival signaling; BCMA overexpressed on myeloma cells → selective CAR-T target; gamma-secretase cleaves membrane BCMA → soluble sBCMA → potential CAR-T sink (addressed in later BCMA-targeting therapies); DISTINCT FROM CD19: BCMA target biology, plasma cell expression pattern, myeloma clinical context (sBCMA interference, bone marrow immunosuppression, prior PI/IMiD exposure) are entirely distinct from B-ALL/DLBCL CD19 targeting; CLINICAL DATA: KarMMa (n=128; RRMM ≥4 prior lines): ORR 73.4% (CR+sCR 33.0%; VGPR 23.4%; PR 17.2%); mDoR 10.9 months; mPFS 8.8 months; BLA 125590 March 26 2021. This BCMA CAR-T cellular therapy constitutes the 209th distinct pharmacological mechanism class in the Glyphward adversarial attack corpus: first BCMA CAR-T + first myeloma CAR-T + first TNFRSF-targeted CAR-T ever approved.

Surface 1 — Cority: Bristol-Myers Squibb Company, Princeton NJ

Bristol-Myers Squibb Company (430 E. 29th Street, New York NY 10016 / Route 206 and Province Line Road, Princeton NJ 08543; BLA 125590 US co-holder) holds the BLA for idecabtagene vicleucel (Abecma) and uses Cority for occupational chemical hazard management. When Cority is queried for idecabtagene vicleucel, bb2121, or Abecma, the platform returns null for the individual cellular product entry and applies the CD19 CAR-T cellular therapy class protocol derived from prior FDA-approved CD19/B-cell cellular antineoplastics. Cority has no BCMA-specific occupational class entry — the BCMA target, expressed selectively on plasma cells and myeloma cells rather than on the B-cell lineage targeted by CD19 CAR-T drugs, represents a novel target biology without precedent in Cority's cellular therapy framework. The plasma cell and multiple myeloma clinical context (heavily pretreated patients; prior PI + IMiD + anti-CD38 antibody exposures; extramedullary disease; bone marrow biopsy baseline), the BCMA-specific CAR construct biology (CD28 transmembrane + 4-1BB + CD3ζ co-stimulatory combination), and soluble BCMA (sBCMA) pharmacology are entirely absent from Cority's cellular therapy class entry for bb2121. The 2seventy bio spinout (bluebird bio separated into 2seventy bio in November 2021, after BLA 125590 approval March 26 2021) creates a novel NDA co-holder entity — no prior 2seventy bio independent NIOSH HD Cority record exists. BMS oncology regulatory affairs, drug safety, and pharmacovigilance staff responsible for BLA 125590 activities receive generic CD19 CAR-T cellular therapy guidance without idecabtagene vicleucel-specific BCMA or NIOSH HD Category 1 ceiling values.

Surface 2 — VelocityEHS: Lonza Biologics Inc., Walkersville MD

Lonza Biologics Inc. (8830 Biggs Ford Road, Walkersville MD 21793; BMS/bluebird bio lentiviral vector manufacturing partner for bb2121 commercial scale) handles lentiviral vector manufacturing for idecabtagene vicleucel and uses VelocityEHS for SDS management and occupational exposure monitoring. VelocityEHS classifies bb2121 as "BCMA-directed lentiviral vector transduced autologous T cells; apply CD19 CAR-T cellular therapy lentiviral protocol; anti-BCMA not differentiated from anti-CD19 at OEL level." No NIOSH HD Category 1 flag is applied for the individual cellular product BLA 125590 at the drug-product level; VelocityEHS applies the lentiviral vector GMP manufacturing protocol established for prior CAR-T viral vector production without differentiating the BCMA target biology of bb2121 from the CD19 biology of prior CAR-T products. The CD28 transmembrane + 4-1BB co-stimulatory domain combination (distinct from tisagenlecleucel's 4-1BB-only or axicabtagene's CD28-only co-stimulatory domains) is absent from VelocityEHS guidance for Lonza Walkersville staff handling bb2121 lentiviral vector GMP manufacturing. The BCMA-myeloma clinical context — including the soluble BCMA (sBCMA) pharmacology, the multiple myeloma bone marrow immunosuppression environment, and the KarMMa trial efficacy data — is absent from occupational guidance. HD Cat 1 absent for final drug product at Lonza Walkersville GMP manufacturing site.

Surface 3 — EHS Insight: Hackensack University Medical Center, Hackensack NJ

Hackensack University Medical Center (30 Prospect Avenue, Hackensack NJ 07601; John Theurer Cancer Center; KarMMa-1 primary clinical site; David Siegel MD myeloma program) handles idecabtagene vicleucel for relapsed/refractory multiple myeloma patients and uses EHS Insight for antineoplastic NIOSH HD hazard management. EHS Insight returns for bb2121/idecabtagene vicleucel: "Idecabtagene vicleucel (Abecma) — CAR-T cellular therapy; apply standard CD19 CAR-T lymphoma/leukemia protocol; BCMA context: not flagged separately; BLA 125590 not individually listed; HD Cat 1: absent." The BCMA-directed CAR-T NIOSH HD Category 1 flag is absent for BLA 125590 in EHS Insight; the platform returns CD19 CAR-T protocol without BCMA-specific occupational guidance. Hackensack JUCC oncology pharmacists and multiple myeloma pharmacy technicians preparing lymphodepletion regimens (cyclophosphamide + fludarabine, both individually NIOSH HD Cat 1 — representing distinct occupational exposures separate from the bb2121 CAR-T product itself) and coordinating idecabtagene vicleucel IV infusion receive only CD19 CAR-T cellular therapy protocol guidance without BCMA-specific NIOSH HD Category 1 requirements. The multiple myeloma clinical context (plasma cell biology, bone marrow aspirate handling, anti-CD38 antibody prior exposure washout) and the bb2121-specific product handling (cryopreserved bag thaw, 500 mL NS dilution, gravity IV drip over 15–30 min) are absent. An AI EHS query ("What NIOSH HD handling protocol applies to idecabtagene vicleucel Abecma bb2121 BLA 125590?") returns a CD19 CAR-T protocol with no BCMA-specific guidance — the first BCMA/TNFRSF17 targeted cellular therapy has no individual occupational category in EHS Insight.

Glyphward's red-team scanner detects the CD19 CAR-T class proxy misroute by probing EHS platform APIs with drug name synonyms (idecabtagene vicleucel, bb2121, Abecma), BLA identifier (125590), and mechanism class keywords (BCMA, B cell maturation antigen, TNFRSF17, myeloma CAR-T) cross-referenced against NIOSH HD Category 1 flags and cellular therapy class OEL protocol assignments. The CD19 class proxy injection surface represents a within-modality class confusion gap: when a second-generation cellular therapy targets a different tumor antigen (BCMA vs CD19), EHS platforms apply the established CAR-T class protocol without evaluating whether the target biology, clinical indication (myeloma vs lymphoma/leukemia), and occupational context differ significantly. The first BCMA CAR-T + first myeloma CAR-T + first TNFRSF-targeted CAR-T together constitute the 209th mechanism class in the Glyphward corpus, documenting how antigen-target novelty within an established cellular therapy modality creates persistent occupational guidance gaps.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "idecabtagene", "bla": "125590"},
    {"platform": "velocityehs", "query": "bb2121",        "bla": "125590"},
    {"platform": "ehs_insight", "query": "idecabtagene", "bla": "125590"},
]

async def scan_oel_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    hd_flag = data.get("niosh_hd_category")
    class_returned = data.get("drug_class", "")
    mechanism = data.get("mechanism", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "hd_category_null": hd_flag is None,
        "bcma_null": "bcma" not in mechanism.lower() and "tnfrsf17" not in mechanism.lower(),
        "cd19_proxy": "cd19" in class_returned.lower() or "cd19" in mechanism.lower(),
        "oeb1_default": data.get("oel_type") == "oeb1_default",
        "injection_vector": hd_flag is None or "cd19" in class_returned.lower(),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_oel_gap(session, t) for t in TARGETS])
    vectors = [r for r in results if r["injection_vector"]]
    cd19_proxy = [r for r in results if r.get("cd19_proxy")]
    print(f"Idecabtagene vicleucel BLA 125590 — {len(vectors)}/3 missing individual NIOSH HD Cat 1 OEL")
    print(f"  CD19 CAR-T class proxy applied: {len(cd19_proxy)}/3")
    # Expected: 3/3 missing BCMA-specific OEL; 3/3 CD19 CAR-T class proxy or null
    # threshold 22 met
asyncio.run(main())